Glucagon-like Peptide 1 Receptor Agonists for the Treatment of Obstructive Sleep Apnea：a meta-analysis.

IF 5.6 2区医学 Q1 Medicine

Sleep Pub Date : 2024-11-29 DOI:10.1093/sleep/zsae280

Mingxia Li, Hong Lin, Qianru Yang, Xiaolong Zhang, Qiong Zhou, Jiankuan Shi, Fangfang Ge

{"title":"Glucagon-like Peptide 1 Receptor Agonists for the Treatment of Obstructive Sleep Apnea：a meta-analysis.","authors":"Mingxia Li, Hong Lin, Qianru Yang, Xiaolong Zhang, Qiong Zhou, Jiankuan Shi, Fangfang Ge","doi":"10.1093/sleep/zsae280","DOIUrl":null,"url":null,"abstract":"Study objectives: Obstructive sleep apnea (OSA) is characterized by disordered breathing during sleep and is associated with major cardiovascular complications. Glucagon-like peptide 1 receptor agonists (GLP-1RA) as an important treatment for obesity and diabetes mellitus show promising therapeutic prospect in OSA. We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.Methods: We searched the PubMed and Web of Science databases (published until July 1, 2024), The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by apnea-hypopnea index (AHI).Results: Six studies with a total of 1067 participants enrolled. GLP-1RA significantly decreased AHI with an estimated treatment difference of-9.48 events per hour (95% CI, -12.56 to -6.40, I2=92%). The change in weight was -10.99kg and BMI was -1.60kg/m2. The mean difference in SBP was -4.81mmHg and in DBP was -0.32 mmHg. Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI, -25.93 to-17.79) vs -5.10 events per hour (95% CI, -6.95 to-3.26). Obese individuals experienced a more significant decrease in AHI with an estimated treatment difference of-12.93 events per hour vs -4.31 events per hour. The application of CPAP and the duration of follow-up did not affect the therapeutic effect.Conclusion: GLP-1RA could significantly reduce the severity of OSA, and also lead to weight loss and lower blood pressure. Further high-quality RCTs are needed to explore different GLP-1RA treatments and durations in OSA, and identify patient subgroups that may benefit the most.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sleep/zsae280","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Study objectives: Obstructive sleep apnea (OSA) is characterized by disordered breathing during sleep and is associated with major cardiovascular complications. Glucagon-like peptide 1 receptor agonists (GLP-1RA) as an important treatment for obesity and diabetes mellitus show promising therapeutic prospect in OSA. We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.

Methods: We searched the PubMed and Web of Science databases (published until July 1, 2024), The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by apnea-hypopnea index (AHI).

Results: Six studies with a total of 1067 participants enrolled. GLP-1RA significantly decreased AHI with an estimated treatment difference of-9.48 events per hour (95% CI, -12.56 to -6.40, I2=92%). The change in weight was -10.99kg and BMI was -1.60kg/m2. The mean difference in SBP was -4.81mmHg and in DBP was -0.32 mmHg. Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI, -25.93 to-17.79) vs -5.10 events per hour (95% CI, -6.95 to-3.26). Obese individuals experienced a more significant decrease in AHI with an estimated treatment difference of-12.93 events per hour vs -4.31 events per hour. The application of CPAP and the duration of follow-up did not affect the therapeutic effect.

Conclusion: GLP-1RA could significantly reduce the severity of OSA, and also lead to weight loss and lower blood pressure. Further high-quality RCTs are needed to explore different GLP-1RA treatments and durations in OSA, and identify patient subgroups that may benefit the most.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Sleep Medicine-Neurology (clinical)

CiteScore

8.70

自引率

10.70%

发文量

期刊介绍： SLEEP® publishes findings from studies conducted at any level of analysis, including: Genes Molecules Cells Physiology Neural systems and circuits Behavior and cognition Self-report SLEEP® publishes articles that use a wide variety of scientific approaches and address a broad range of topics. These may include, but are not limited to: Basic and neuroscience studies of sleep and circadian mechanisms In vitro and animal models of sleep, circadian rhythms, and human disorders Pre-clinical human investigations, including the measurement and manipulation of sleep and circadian rhythms Studies in clinical or population samples. These may address factors influencing sleep and circadian rhythms (e.g., development and aging, and social and environmental influences) and relationships between sleep, circadian rhythms, health, and disease Clinical trials, epidemiology studies, implementation, and dissemination research.